secwatch.observer — SEC 8-K summary
======================================

Issuer:     CURIS INC (CRIS)
CIK:        0001108205
Form:       8-K
Filed at:   2024-05-07T23:59:59+00:00
Accession:  0001108205-24-000032
Event type: earnings
Sentiment:  neutral
Materiality: 0.55
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Curis Q1 net loss $11.9M ($2.05/sh); cash $40.7M; topline AML data May 14
-------------------------------------------------------------------------

- Net loss $11.9M vs $11.6M Q1 2023; revenue $2.1M (Erivedge royalties) vs $2.3M.
- Cash, equivalents and investments $40.7M as of March 31, 2024; expected to fund operations into 2025.
- Topline clinical data from TakeAim Leukemia study (emavusertib monotherapy in R/R AML) to be released May 14, 2024.
- Abstracts accepted for ASCO (May 31-Jun 4) and EHA (Jun 13-16); posters on FLT3m and mSF cohorts.
- Updated data for R/R PCNSL and frontline AML triplet combo expected late 2024.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1108205/000110820524000032/0001108205-24-000032-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1108205/000110820524000032/cris-20240507.htm
  HTML page:      https://secwatch.observer/filing/0001108205-24-000032

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer